# US 2022/0031754 A1 · Cells comprising non-hla restricted t cell receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031754 A1
- Document ID: US20220031754A1
- Status: Published application
- Kind: A1
- Application number: 17/505,515
- Filed: 2021-10-19
- Published: 2022-02-03
- Earliest claimed: 2018-02-11
- Assignees: Memorial Sloan Kettering Cancer Center
- Applicants: Memorial Sloan-Kettering Cancer Center
- Inventors: Michel Sadelain; Jorge A. Mansilla-Soto; Justin Eyquem; Anton Dobrin
- Web page: https://patentgrep.com/patent/US20220031754A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/421: {Immunoglobulin superfamily}
- A61K 40/4211: {CD19 or B4}
- A61K 40/4212: {CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2}
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61K 40/4232: {Tumor necrosis factors [TNF] or CD70}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C12N 5/0636: {T lymphocytes}
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2319/03: containing a transmembrane segment
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.

## Claims

### Claim 1

A recombinant T cell receptor (TCR) comprising an antigen binding chain that comprises an extracellular antigen-binding domain and a constant domain, wherein the recombinant TCR binds to an antigen in an HLA-independent manner, wherein the constant domain comprises a native or modified TRAC polypeptide and/or a native or modified TRBC polypeptide.

### Claim 2 (depends on 1)

The recombinant TCR of claim 1, wherein the antigen binding chain comprises:
i) a first antigen-binding chain comprising an antigen-binding fragment of a heavy chain variable region (VH) of an antibody; and
ii) a second antigen-binding chain comprising an antigen-binding fragment of a light chain variable region (VL) of the antibody;
wherein the first and second antigen-binding chains each comprise the TRAC polypeptide or the TRBC polypeptide, wherein at least one of the TRAC polypeptide and the TRBC polypeptide is endogenous, and the first and the second antigen-binding chains bind to the antigen.

### Claim 3 (depends on 1)

The recombinant TCR of claim 1, wherein the antigen binding chain comprises:
i) a first antigen-binding chain comprising an antigen-binding fragment of a heavy chain variable region (VH) of an antibody; and
ii) a second antigen-binding chain comprising an antigen-binding fragment of a light chain variable region (VL) of the antibody;
wherein the first and second antigen-binding chains each comprise the TRAC polypeptide or the TRBC polypeptide, and the first and the second antigen-binding chains bind to the antigen with a dissociation constant (KD) of about 1×10−8 M or less.

### Claim 4 (depends on 1)

The recombinant TCR of claim 1, wherein the recombinant TCR binds to a tumor antigen, optionally wherein the tumor antigen is selected from the group consisting of CD19, MUC16, MUC1, CAIX, CEA, CD8, CD7, CD10, CD20, CD22, CD30, CLL1, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD133, CD138, EGP-2, EGP-40, EpCAM, Erb-B2, Erb-B3, Erb-B4, FBP, Fetal acetylcholine receptor, folate receptor-a, GD2, GD3, HER-2, hTERT, IL-13R-α2, κ-light chain, KDR, LeY, L1 cell adhesion molecule, MAGE-A1, Mesothelin, ERBB2, MAGEA3, p53, MART1, GP100, Proteinase3 (PR1), Tyrosinase, Survivin, hTERT, EphA2, NKG2D ligands, NY-ESO-1, oncofetal antigen (h5T4), PSCA, PSMA, ROR1, TAG-72, VEGF-R2, WT-1, BCMA, CD123, CD44V6, NKCS1, EGF1R, EGFR-VIII, and CD99, CD70, ADGRE2, CCR1, LILRB2, LILRB4, PRAME, and ERBB.

### Claim 5 (depends on 1)

The recombinant TCR of claim 1, wherein the antigen that has a low density on the cell surface has a density of less than about 10,000 molecules per cell.

### Claim 6 (depends on 1)

An immunoresponsive cell comprising a recombinant TCR of claim 1.

### Claim 7 (depends on 2)

An immunoresponsive cell comprising a recombinant TCR of claim 2.

### Claim 8 (depends on 3)

An immunoresponsive cell comprising a recombinant TCR of claim 3.

### Claim 9 (depends on 6)

The immunoresponsive cell of claim 6, wherein the recombinant TCR is expressed by a transgene that is integrated at an endogenous gene locus of the immunoresponsive cell.

### Claim 10 (depends on 9)

The immunoresponsive cell of claim 9, wherein the endogenous gene locus is a CD3δ locus, a CD3ε locus, a CD247 locus, a B2M locus, a TRAC locus, a TRBC locus, a TRDC locus and/or a TRGC locus.

### Claim 11 (depends on 9)

The immunoresponsive cell of claim 9, wherein the endogenous expression of a TCR comprising a native TCR α chain and/or a native TCR β chain is disrupted or abolished in the immunoresponsive cell, thereby preventing or eliminating mispairing between the recombinant TCR and a native TCR α chain and/or a native TCR β chain in the immunoresponsive cell.

### Claim 12 (depends on 9)

The immunoresponsive cell of claim 9, wherein the endogenous gene locus is a first endogenous TCR locus, and a second endogenous TCR locus that is different from the first endogenous TCR locus is modified to eliminate the expression of an endogenous TCR chain encoded by the second endogenous TCR locus.

### Claim 13 (depends on 6)

The immunoresponsive cell of claim 6, wherein the immunoresponsive cell is a B cell, a T cell, a Natural Killer (NK) cell, a pluripotent stem cell from which a lymphoid cell may be differentiated, or a combination thereof.

### Claim 14 (depends on 13)

The immunoresponsive cell of claim 13, wherein the immunoresponsive cell is a T cell, optionally wherein the T cell is selected from the group consisting of a cytotoxic T lymphocyte (CTL), a regulatory T cell, and a Natural Killer T (NKT) cell.

### Claim 15 (depends on 6)

A pharmaceutical composition comprising an effective amount of an immunoresponsive cell of claim 6 and a pharmaceutically acceptable excipient.

### Claim 16 (depends on 6)

A method of reducing tumor burden in a subject, and/or treating or preventing a neoplasm in a subject, and/or lengthening survival of a subject having a neoplasm, the method comprising administering to the subject an effective amount of the immunoresponsive cells of claim 6.

### Claim 17

A method for producing an antigen-specific immunoresponsive cell, the method comprising introducing into an immunoresponsive cell a nucleic acid molecule encoding a recombinant TCR comprising an antigen binding chain that comprises an extracellular antigen-binding domain and a constant domain, wherein the recombinant TCR binds to an antigen in an HLA-independent manner, wherein the constant domain comprises a native or modified TRAC polypeptide and/or a native or modified TRBC polypeptide.

### Claim 18 (depends on 1)

A nucleotide acid molecule encoding a recombinant TCR of claim 1.

### Claim 19 (depends on 18)

A vector comprising the nucleic acid molecule of claim 18.

### Claim 20 (depends on 6)

A kit comprising immunoresponsive cell of claim 6, optionally wherein the kit further comprises a container.
